Myasthenia gravis: past, present, and future.
暂无分享,去创建一个
[1] M. Walker. Case Showing the Effect of Prostigmin on Myasthenia Gravis , 1935, Proceedings of the Royal Society of Medicine.
[2] H. Link,et al. Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. , 1997, Clinical immunology and immunopathology.
[3] R. Hohlfeld,et al. Autoimmune human T lymphocytes specific for acetylcholine receptor , 1984, Nature.
[4] F. Shi,et al. Natural killer cells determine the outcome of B cell–mediated autoimmunity , 2000, Nature Immunology.
[5] I. Spreadbury,et al. AChR phosphorylation and indirect inhibition of AChR function in seronegative MG , 2002, Neurology.
[6] A. Engel,et al. Ultrastructural Localization of the Terminal and Lytic Ninth Complement Component (C9) at the Motor End‐plate in Myasthenia Gravis , 1979, Journal of neuropathology and experimental neurology.
[7] D. Sanders,et al. Steroids have an important role , 2002 .
[8] A. Saoudi,et al. Estrogen Enhances Susceptibility to Experimental Autoimmune Myasthenia Gravis by Promoting Type 1-Polarized Immune Responses1 , 2005, The Journal of Immunology.
[9] P. Christadoss,et al. Induction of Myasthenia Gravis in HLA Transgenic Mice by Immunization with Human Acetylcholine Receptors , 2003, Annals of the New York Academy of Sciences.
[10] J. D. Porter,et al. Conservation of Synapse‐Signaling Pathways at the Extraocular Muscle Neuromuscular Junction , 2002, Annals of the New York Academy of Sciences.
[11] J. Keesey,et al. “Crisis” in myasthenia gravis: An historical perspective , 2002, Muscle & nerve.
[12] B. Katirji,et al. Electrodiagnostic approach to the patient with suspected neuromuscular junction disorder. , 2002, Neurologic clinics.
[13] J. Michelson,et al. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. , 1978, The New England journal of medicine.
[14] J. Howard,et al. T cell recognition of muscle acetylcholine receptor in ocular myasthenia gravis , 2000, Journal of Neuroimmunology.
[15] P. Christadoss,et al. Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein , 2002, Journal of Neuroimmunology.
[16] J. Newsom-Davis,et al. Development of a Thymectomy Trial in Nonthymomatous Myasthenia Gravis Patients Receiving Immunosuppressive Therapy , 2003, Annals of the New York Academy of Sciences.
[17] S. Cohen-Kaminsky,et al. Prospects for a T-cell receptor vaccination against myasthenia gravis , 2005, Expert review of vaccines.
[18] R. Barohn,et al. Evaluation of myosin-reactive antibodies from a panel of myasthenia gravis patients. , 1994, Clinical immunology and immunopathology.
[19] P. Whiting,et al. Acetycholine receptor antibody characteristics in myasthenia gravis Fractionation of α-Bungarotoxin binding site antibodies and their relationship to IgG subclass , 1983, Journal of Neuroimmunology.
[20] B. Xiao,et al. Dendritic cells exposed in vitro to TGF‐β1 ameliorate experimental autoimmune myasthenia gravis , 2002, Clinical and experimental immunology.
[21] A. Vincent,et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies , 2001, Nature Medicine.
[22] P. Christadoss,et al. Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment , 2005 .
[23] R. Horton,et al. The 'embryonic' gamma subunit of the nicotinic acetylcholine receptor is expressed in adult extraocular muscle , 1993, Neurology.
[24] L. Moiola,et al. Epitopes on the beta subunit of human muscle acetylcholine receptor recognized by CD4+ cells of myasthenia gravis patients and healthy subjects. , 1994, The Journal of clinical investigation.
[25] M. Pescovitz. Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[26] J. Atkinson,et al. Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells. , 1989, The Journal of clinical investigation.
[27] H. Kaminski,et al. Molecular architecture of the neuromuscular junction , 2006, Muscle & nerve.
[28] R. Pirskanen,et al. Acetylcholine receptor-reactive T cells in myasthenia gravis: Evidence for the involvement of different subpopulations of T helper cells , 1994, Journal of Neuroimmunology.
[29] J. Ravetch,et al. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. , 2001, Science.
[30] H. Link,et al. Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis. , 2004, Clinical and experimental immunology.
[31] J. Aarli. Titin, thymoma, and myasthenia gravis. , 2001, Archives of neurology.
[32] P. Christadoss,et al. Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis , 2004, Immunogenetics.
[33] I. Bernard,et al. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats. , 1999, Journal of immunology.
[34] J. Wolinsky,et al. Immune studies in human immunodeficiency virus infection with myasthenia gravis , 1990, Neurology.
[35] P. Christadoss. C5 gene influences the development of murine myasthenia gravis. , 1988, Journal of immunology.
[36] Zeng-Yu Wang,et al. T-cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis , 1998, Neurology.
[37] Chuan-zhen Lu,et al. Increase of circulating CD4+CD25+ T cells in myasthenia gravis patients with stability and thymectomy. , 2004, Clinical immunology.
[38] M. Shenoy,et al. The role of major histocompatibility complex genes in myasthenia gravis and experimental autoimmune myasthenia gravis pathogenesis. , 1994, Advances in neuroimmunology.
[39] K. Shigemoto,et al. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG , 2004, Neurology.
[40] G. Patterson,et al. A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. , 2005, The Journal of thoracic and cardiovascular surgery.
[41] John Newsom-Davis,et al. A randomized double‐blind trial of prednisolone alone or with azathioprine in myasthenia gravis , 1998, Neurology.
[42] J. Simpson. Myasthenia Gravis: A New Hypothesis , 1960 .
[43] P. Christadoss,et al. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. , 1998, Journal of immunology.
[44] R. Tindall,et al. A Clinical Therapeutic Trial of Cyclosporine in Myasthenia Gravis a , 1993, Annals of the New York Academy of Sciences.
[45] J. Sonett,et al. Thymectomy in the management of myasthenia gravis. , 2004, Seminars in neurology.
[46] J. Bixby,et al. Agrin orchestrates synaptic differentiation at the vertebrate neuromuscular junction , 1998, Trends in Neurosciences.
[47] S. Meri,et al. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[48] D B Sanders,et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. , 2000, Neurology.
[49] Y. Abe,et al. Induction of myasthenia by immunization against muscle-specific kinase. , 2006, The Journal of clinical investigation.
[50] H. Hartung,et al. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. , 2006, Archives of neurology.
[51] J. Newsom-Davis,et al. Therapy in Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome , 2003, Seminars in neurology.
[52] H. Kaminski,et al. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. , 2002, The Journal of clinical investigation.
[53] A. Vandenbark,et al. TCR peptide therapy decreases the frequency of encephalitogenic T cells in the periphery and the central nervous system , 1992, Journal of Neuroimmunology.
[54] P. Christadoss,et al. Role of IL-5 during primary and secondary immune response to acetylcholine receptor , 2002, Journal of Neuroimmunology.
[55] H. Link,et al. Interferon‐γ‐modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis , 2004 .
[56] A. Engel,et al. Mechanisms of acetylcholine receptor loss from the neuromuscular junction. , 1982, Ciba Foundation symposium.
[57] R. Ulevitch,et al. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis , 1978, The Journal of experimental medicine.
[58] P. Christadoss,et al. Resistance to Experimental Autoimmune Myasthenia Gravis in IL-6-Deficient Mice Is Associated with Reduced Germinal Center Formation and C3 Production1 , 2002, The Journal of Immunology.
[59] P. Karachunski,et al. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. , 1997, The Journal of clinical investigation.
[60] G. Stoll,et al. Increased serum levels of the interferon-&ggr;–inducing cytokine interleukin-18 in myasthenia gravis , 2002, Neurology.
[61] A. Vincent,et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis , 2004, Annals of neurology.
[62] S. Fuchs,et al. Overexpression of IFN-Induced Protein 10 and Its Receptor CXCR3 in Myasthenia Gravis1 , 2005, The Journal of Immunology.
[63] L Matis,et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. , 1999, Circulation.
[64] L. Rowland. Controversies about the treatment of myasthenia gravis. , 1980, Journal of neurology, neurosurgery, and psychiatry.
[65] John C. Keesey,et al. Clinical evaluation and management of myasthenia gravis , 2004, Muscle & nerve.
[66] H. Link,et al. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells , 2004, Neurobiology of Disease.
[67] J. Howard,et al. Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[68] W. L. Nastuk,et al. Search for a neuromuscular blocking agent in the blood of patients with myasthenia gravis. , 1959, The American journal of medicine.
[69] B. Scallon,et al. Anti-TNF-α Antibodies Suppress the Development of Experimental Autoimmune Myasthenia Gravis , 2002 .
[70] P. Christadoss,et al. Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. , 2005, Journal of autoimmunity.
[71] Richard J. Jones,et al. Treatment of refractory myasthenia: “Rebooting” with high‐dose cyclophosphamide , 2003, Annals of neurology.
[72] J. Montoro,et al. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study , 2005, Clinical Neurology and Neurosurgery.
[73] R. Hohlfeld,et al. Induction of HLA-DR expression on human myoblasts with interferon-gamma. , 1990, The American journal of pathology.
[74] F. Shi,et al. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. , 2000, International immunology.
[75] E. Rieber,et al. Treatment of myasthenia gravis with anti‐CD4 antibody , 1994, Neurology.
[76] M. Sela,et al. Immunomodulation by a dual altered peptide ligand of autoreactive responses to the acetylcholine receptor of peripheral blood lymphocytes of patients with myasthenia gravis. , 2004, Human immunology.
[77] H. Soreq,et al. Acetylcholinesterase — new roles for an old actor , 2001, Nature Reviews Neuroscience.
[78] R. Greenlee,et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. , 1987, The New England journal of medicine.
[79] H. Soreq,et al. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[80] A. Mamalaki,et al. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor α-subunit. Development of an antigen-specific therapeutic strategy , 2005, Journal of Neuroimmunology.
[81] P. Karachunski,et al. Absence of IFN-γ or IL-12 Has Different Effects on Experimental Myasthenia Gravis in C57BL/6 Mice1 , 2000, The Journal of Immunology.
[82] Marsteller Hb. The first American case of myasthenia gravis. , 1988 .
[83] R. Barohn,et al. Myasthenia gravis , 2000, Neurology.
[84] A. Vincent,et al. Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese , 2004, Neurology.
[85] A. Vincent,et al. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis , 2005, Current opinion in neurology.
[86] J. Lindstrom,et al. Monoclonal antibodies as probes of acetylcholine receptor structure. 2. Binding to native receptor. , 1981, Biochemistry.
[87] A. Saoudi,et al. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. , 2005, Blood.
[88] P. Christadoss,et al. Cooperation of Invariant NKT Cells and CD4+CD25+ T Regulatory Cells in the Prevention of Autoimmune Myasthenia1 , 2005, The Journal of Immunology.
[89] J. Hemmen,et al. Cytokine-modulated regulation of helper T cell populations. , 2000, Journal of theoretical biology.
[90] R. Longhi,et al. Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. , 1999, The Journal of clinical investigation.
[91] E. Ciafaloni. Mycophenolate mofetil and myasthenia gravis , 2005 .
[92] P. Christadoss,et al. HLA-DQ6 transgenic mice resistance to experimental autoimmune myasthenia gravis is linked to reduced acetylcholine receptor-specific IFN-gamma, IL-2 and IL-10 production. , 2001, Journal of autoimmunity.
[93] G. Biesecker,et al. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. , 1989, Journal of immunology.
[94] N. Robertson. Enumerating neurology. , 2000, Brain : a journal of neurology.
[95] S. Fuchs,et al. Suppression of experimental myasthenia gravis, a B cell‐mediated autoimmune disease, by blockade of IL‐18 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[96] H. Oosterhuis,et al. Myasthenia gravis and myasthenic syndromes. , 1992, Current opinion in neurology and neurosurgery.
[97] V. Nussenzweig,et al. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids , 1987, The Journal of experimental medicine.
[98] J. Patrick,et al. Autoimmune Response to Acetylcholine Receptor , 1973, Science.
[99] Hanns Lochmüller,et al. What’s in the serum of seronegative MG and LEMS? , 2002, Neurology.
[100] A. Vincent,et al. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis , 1996, Journal of Neuroimmunology.
[101] R. Garman,et al. Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis , 1999, Journal of Neuroimmunology.
[102] L. Balcer,et al. Strategies for Treatment of Myasthenia Gravis a , 1993, Annals of the New York Academy of Sciences.
[103] D. Richman,et al. Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[104] R. Ruff,et al. Single-channel basis of slow inactivation of Na+ channels in rat skeletal muscle. , 1996, The American journal of physiology.
[105] P. Christadoss,et al. Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR , 2000, Journal of Neuroimmunology.
[106] S. Berrih-Aknin,et al. Major pathogenic effects of anti-MuSK antibodies in Myasthenia Gravis , 2006, Journal of Neuroimmunology.
[107] R. Mantegazza,et al. Anti‐titin and Antiryanodine Receptor Antibodies in Myasthenia Gravis Patients with Thymoma , 1998, Annals of the New York Academy of Sciences.
[108] M. Milani,et al. Absence of IL-4 Facilitates the Development of Chronic Autoimmune Myasthenia Gravis in C57BL/6 Mice1 , 2003, The Journal of Immunology.
[109] R. Pascuzzi,et al. THE HISTORY OF MYASTHENIA GRAVIS , 1961, Medical History.
[110] H. Kaminski,et al. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis , 2004, Experimental Neurology.
[111] K. Toyka,et al. Outcome in juvenile-onset myasthenia gravis: a retrospective study with long-term follow-up of 79 patients , 1997, Journal of Neurology.
[112] H. Weiner,et al. Induction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells , 2001, Immunological reviews.
[113] G. Gronseth,et al. Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review) , 2000, Neurology.
[114] Zeng-Yu Wang,et al. Myasthenia in SCID mice grafted with myasthenic patient lymphocytes , 1999, Neurology.
[115] N. Gilhus,et al. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. , 2005, Archives of neurology.
[116] H. B. Marsteller. The first American case of myasthenia gravis. , 1988, Archives of Neurology.
[117] R. Sterz,et al. Postjunctional characteristics of the endplates in mammalian fast and slow muscles , 1983, Pflügers Archiv.
[118] D. Drachman,et al. Specific immunotherapy of experimental myasthenia gravis in vitro: the "guided missile" strategy. , 2001, Cellular immunology.
[119] H. Eng,et al. Human monoclonal immunoglobulins that bind the human acetylcholine receptor , 1987, European journal of immunology.
[120] A. Vincent,et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody–positive myasthenia gravis , 2005, Annals of neurology.
[121] P. Christadoss,et al. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis , 2002, Journal of Neuroimmunology.
[122] S. J. Wood,et al. The contribution of postsynaptic folds to the safety factor for neuromuscular transmission in rat fast‐ and slow‐twitch muscles. , 1997, The Journal of physiology.
[123] P. Distefano,et al. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation and is a functional receptor for agrin. , 1996, Cold Spring Harbor symposia on quantitative biology.
[124] M. Shenoy,et al. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. , 1994, Journal of immunology.
[125] J. Griffin,et al. Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases , 2001, Neurology.